Financial Performance - The company's revenue for Q1 2024 was CNY 234,624,438.88, representing a 5.78% increase compared to CNY 221,797,622.60 in the same period last year[5]. - Net profit attributable to shareholders was CNY 58,872,271.43, up 6.51% from CNY 55,273,336.61 year-on-year[5]. - The total operating revenue for Q1 2024 was CNY 234,624,438.88, an increase of 5.9% compared to CNY 221,797,622.60 in Q1 2023[25]. - The net profit for Q1 2024 reached CNY 58,872,271.43, representing a 9.4% increase from CNY 55,273,336.61 in Q1 2023[26]. - The total operating costs for Q1 2024 were CNY 170,660,081.11, up from CNY 157,112,950.31 in the same period last year, reflecting a year-over-year increase of 8.8%[25]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 20.80% to CNY 134,109,804.54, compared to CNY 111,020,049.15 in the previous year[5]. - Total cash inflow from operating activities reached CNY 301,545,548.82, up from CNY 271,803,192.39, reflecting a growth of 10.9%[30]. - Cash outflow from operating activities was CNY 167,435,744.28, compared to CNY 160,783,143.24, indicating a rise of 4.1%[30]. - The net cash flow from investing activities was -CNY 49,693,920.20, an improvement from -CNY 98,976,811.16 in the previous period[30]. - The ending cash and cash equivalents balance increased to CNY 512,227,863.05 from CNY 51,925,842.84, marking a significant rise[31]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 1,737,209,174.50, a 5.43% increase from CNY 1,647,809,834.45 at the end of the previous year[5]. - The total liabilities increased to CNY 205,276,691.49 in Q1 2024 from CNY 174,749,622.87 in Q1 2023, marking a rise of 17.4%[23]. - The total current assets as of March 31, 2024, amounted to CNY 1,171,882,824.56, an increase from CNY 1,160,704,900.90 at the beginning of the period, reflecting a growth of approximately 0.15%[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,939[15]. - The company reported a total of 238,000,000 shares under lock-up prior to the IPO, with a release date set for 2026[19]. - The number of shares held by the top ten unrestricted shareholders includes 904,783 shares held by Gao Canxuan and 770,798 shares held by Lu Xiaoxu[18]. - The company has a total of 4,593,003 shares under lock-up from offline placements, with a release date in March 2024[19]. Inventory and Receivables Management - Accounts receivable decreased by 40.20% to CNY 20,457,486.94, attributed to improved management of receivables[10]. - Inventory decreased by 33.70% to CNY 69,823,974.78, due to effective inventory management during the reporting period[10]. - Inventory decreased significantly from CNY 105,315,599.46 to CNY 69,823,974.78, indicating a reduction of approximately 33.7%[21]. - Accounts receivable decreased from CNY 34,207,790.42 to CNY 20,457,486.94, a decline of about 40.2%[21]. Government Subsidies and Other Income - The company received government subsidies amounting to CNY 1,340,821.47, contributing to other income growth of 63.03%[12]. - The company received CNY 5,534,842.83 in other cash related to operating activities, compared to CNY 2,021,722.59 previously, showing a growth of 173.5%[30]. Earnings and Expenses - The company's basic earnings per share decreased by 19.05% to CNY 0.1700, down from CNY 0.2100 in the same period last year[5]. - The research and development expenses for Q1 2024 were CNY 10,242,656.68, slightly decreased from CNY 10,326,983.01 in the previous year[26]. - The company paid CNY 30,202,401.32 in taxes, up from CNY 25,398,009.39, reflecting an 18.4% increase[30]. Financial Management - The company is actively managing its financial assets, with a focus on optimizing liquidity and reducing inventory levels[20]. - The company has shown a significant increase in other non-current assets, which rose to CNY 292,298,503.11 from CNY 213,799,229.97 year-over-year, reflecting a growth of 36.7%[23]. - The company is focusing on expanding its market presence and developing new products, although specific details on new products or technologies were not provided in the content[28]. Audit Status - The company has not undergone an audit for the Q1 2024 report[32].
民生健康(301507) - 2024 Q1 - 季度财报